<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00007397</url>
  </required_header>
  <id_info>
    <org_study_id>958</org_study_id>
    <secondary_id>R43HL065117</secondary_id>
    <nct_id>NCT00007397</nct_id>
  </id_info>
  <brief_title>Age, Risk Factors for CVD and Cognitive Functioning</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Heart, Lung, and Blood Institute (NHLBI)</source>
  <brief_summary>
    <textblock>
      To relate cardiovascular disease (CHD) risk factors to cognitive performance among&#xD;
      middle-aged and elderly men and women over a 10 year longitudinal study period.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND:&#xD;
&#xD;
      The Framingham Heart Study is a major epidemiological investigation of prospective&#xD;
      relationships between risk factors for the development of cardiovascular disease (CVD risk&#xD;
      factors) and CVD risk factor outcomes. The Framingham Study and other large, prospective&#xD;
      studies have resulted in an extensive literature on the impact of CVD risk factors (including&#xD;
      age) and CVD outcomes. Comparatively, there have been many fewer studies of the impact of CVD&#xD;
      risk factors on cognitive functioning, and possibly no studies of the effect of objectively&#xD;
      measured, competing risk factors on cognitive functioning.&#xD;
&#xD;
      DESIGN NARRATIVE:&#xD;
&#xD;
      Dr. Elias and colleagues used cardiovascular risk factor data from the Framingham Heart Study&#xD;
      (N= 2,123) in a prospective design allowing them to relate CVD risk factors (including age&#xD;
      and gender) to two outcome measures: (1) level of cognitive performance and (2) change in&#xD;
      cognitive performance over a 10 year longitudinal study period. The overall goals were to&#xD;
      determine the best multivariate combination of biological and psychosocial risk factors for&#xD;
      the prediction of lowered cognitive ability in middle-aged and elderly men and women, and to&#xD;
      evaluate the relative impact of age, gender, and other biological and psychosocial risk&#xD;
      factors on cognitive functioning.&#xD;
&#xD;
      The study completion date listed in this record was obtained from the &quot;End Date&quot; entered in&#xD;
      the Protocol Registration and Results System (PRS) record.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2000</start_date>
  <completion_date type="Actual">January 2004</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <condition>Cardiovascular Diseases</condition>
  <condition>Heart Diseases</condition>
  <condition>Neurologic Manifestations</condition>
  <eligibility>
    <criteria>
      <textblock>
        No eligibility criteria&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Merrill Elias</last_name>
    <affiliation>Boston University</affiliation>
  </overall_official>
  <reference>
    <citation>Elias MF, Elias PK, Sullivan LM, Wolf PA, D'Agostino RB. Lower cognitive function in the presence of obesity and hypertension: the Framingham heart study. Int J Obes Relat Metab Disord. 2003 Feb;27(2):260-8. doi: 10.1038/sj.ijo.802225.</citation>
    <PMID>12587008</PMID>
  </reference>
  <reference>
    <citation>Elias MF, Sullivan LM, D'Agostino RB, Elias PK, Beiser A, Au R, Seshadri S, DeCarli C, Wolf PA. Framingham stroke risk profile and lowered cognitive performance. Stroke. 2004 Feb;35(2):404-9. doi: 10.1161/01.STR.0000103141.82869.77. Epub 2004 Jan 15.</citation>
    <PMID>14726556</PMID>
  </reference>
  <reference>
    <citation>Elias PK, Elias MF, D'Agostino RB, Sullivan LM, Wolf PA. Serum cholesterol and cognitive performance in the Framingham Heart Study. Psychosom Med. 2005 Jan-Feb;67(1):24-30. doi: 10.1097/01.psy.0000151745.67285.c2.</citation>
    <PMID>15673620</PMID>
  </reference>
  <verification_date>December 2005</verification_date>
  <study_first_submitted>December 19, 2000</study_first_submitted>
  <study_first_submitted_qc>December 18, 2000</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 19, 2000</study_first_posted>
  <last_update_submitted>May 12, 2016</last_update_submitted>
  <last_update_submitted_qc>May 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 13, 2016</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neurologic Manifestations</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

